Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function: Possible links between diabetes and atherosclerosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 6, 2010, Pages 561-571

  Moheimani, Fatemeh ^a,c   Morgan, Philip E ^a,c   van Reyk, David M ^b   Davies, Michael J ^a,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c University of Sydney   (Australia)

Author keywords

Advanced glycation end products; Diabetes associated atherosclerosis; Glycated proteins; Proteasome; Protein turnover; Reactive aldehydes

Indexed keywords

ALDEHYDE; CASPASE; CELL EXTRACT; CHYMOTRYPSIN; GLYCOLALDEHYDE; GLYCOSYLATED PROTEIN; GLYOXAL; METHYLGLYOXAL; PROTEASOME; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GLYCATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS;

ALDEHYDES; ANIMALS; ATHEROSCLEROSIS; CATTLE; CELL LINE; DIABETES MELLITUS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MACROPHAGES; MICE; PROTEASOME ENDOPEPTIDASE COMPLEX; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE;

EID: 77952243282     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.02.007     Document Type: Article

References (66)

1. Martinez-Vicente M., Sovak G., Cuervo A.M. Protein degradation and aging. Exp. Gerontol. 2005, 40:622-633.
2. Klare N., Seeger M., Janek K., Jungblut P.R., Dahlmann B. Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation. J. Mol. Biol. 2007, 373:1-10.
3. Hipkiss A.R. Accumulation of altered proteins and ageing: causes and effects. Exp. Gerontol. 2006, 41:464-473.
4. Baynes J.W. The Maillard hypothesis on aging: time to focus on DNA. Ann. N. Y. Acad. Sci. 2002, 959:360-367.
5. Thomas M.C., Baynes J.W., Thorpe S.R., Cooper M.E. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr. Drug Targets 2005, 6:453-474.
6. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005, 67:3-21.
7. Zeng J., Dunlop R.A., Rodgers K.J., Davies M.J. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem. J. 2006, 398:197-206.
8. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadida R., Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 2003, 375:581-592.
9. Kisugi R., Kouzuma T., Yamamoto T., Akizuki S., Miyamoto H., Someya Y., Yokoyama J., Abe I., Hirai N., Ohnishi A. Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin. Chim. Acta 2007, 382:59-64.
10. Anderson M.M., Hazen S.L., Hsu F.F., Heinecke J.W. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest. 1997, 99:424-432.
11. Wells-Knecht K.J., Zyzak D.V., Litchfield J.E., Thorpe S.R., Baynes J.W. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995, 34:3702-3709.
12. Phillips S.A., Thornalley P.J. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur. J. Biochem. 1993, 212:101-105.
13. Thornalley P.J. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen. Pharmacol. 1996, 27:565-573.
14. Hazen S.L., Hsu F.F., d'Avignon A., Heinecke J.W. Human neutrophils employ myeloperoxidase to convert alpha-amino acids to a battery of reactive aldehydes: a pathway for aldehyde generation at sites of inflammation. Biochemistry 1998, 37:6864-6873.
15. Lo T.W., Westwood M.E., McLellan A.C., Selwood T., Thornalley P.J. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N-alpha-acetylarginine, N-alpha-acetylcysteine, and N-alpha-acetyllysine, and bovine serum albumin. J. Biol. Chem. 1994, 269:32299-32305.
16. Ratliff D.M., Vander Jagt D.J., Eaton R.P., Vander Jagt D.L. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II-a clinical research center stud. J. Clin. Endocrinol. Metab. 1996, 81:488-492.
17. Staniszewska M.M., Nagaraj R.H. Upregulation of glyoxalase I fails to normalize methylglyoxal levels: a possible mechanism for biochemical changes in diabetic mouse lenses. Mol. Cell. Biochem. 2006, 288:29-36.
18. Grune T., Davies K.J. The proteasomal system and HNE-modified proteins. Mol. Aspects Med. 2003, 24:195-204.
19. Orlowski M., Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. 2000, 383:1-16.
20. Coux O., Tanaka K., Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 1996, 65:801-847.
21. Kisselev A.F., Goldberg A.L. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 2005, 398:364-378.
22. Bulteau A.L., Verbeke P., Petropoulos I., Chaffotte A.F., Friguet B. Proteasome inhibition in glyoxal-treated fibroblasts and resistance of glycated glucose-6-phosphate dehydrogenase to 20 S proteasome degradation in vitro. J. Biol. Chem. 2001, 276:45662-45668.
23. Morgan P.E., Dean R.T., Davies M.J. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch. Biochem. Biophys. 2002, 403:259-269.
24. Brown B.E., Rashid I., van Reyk D.M., Davies M.J. Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. FEBS J. 2007, 274:1530-1541.
25. Knott H.M., Brown B.E., Davies M.J., Dean R.T. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur. J. Biochem. 2003, 270:3572-3582.
26. Valencia J.V., Weldon S.C., Quinn D., Kiers G.H., De Groot J., TeKoppele J.M., Hughes T.E. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal. Biochem. 2004, 324:68-78.
27. Argirova M., Breipohl W. Comparison between modifications of lens proteins resulted from glycation with methylglyoxal, glyoxal, ascorbic acid, and fructose. J. Biochem. Mol. Toxicol. 2002, 16:140-145.
28. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
29. Hawkins C.L., Morgan P.E., Davies M.J. Quantification of protein modification by oxidants. Free Radic. Biol. Med. 2009, 46:965-988.
30. Zeng J., Davies M.J. Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem. Res. Toxicol. 2005, 18:1232-1241.
31. Odani H., Iijima K., Nakata M., Miyata S., Kusunoki H., Yasuda Y., Hiki Y., Irie S., Maeda K., Fujimoto D. Identification of N(omega)-carboxymethylarginine, a new advanced glycation endproduct in serum proteins of diabetic patients: possibility of a new marker of aging and diabetes. Biochem. Biophys. Res. Commun. 2001, 285:1232-1236.
32. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
33. Jorgensen L., Jenssen T., Joakimsen O., Heuch I., Ingebretsen O.C., Jacobsen B.K. Glycated hemoglobin level is strongly related to the prevalence of carotid artery plaques with high echogenicity in nondiabetic individuals: the Tromso study. Circulation 2004, 110:466-470.
34. Dyer D.G., Dunn J.A., Thorpe S.R., Bailie K.E., Lyons T.J., McCance D.R., Baynes J.W. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J. Clin. Invest. 1993, 91:2463-2469.
35. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A., Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med. 2004, 141:413-420.
36. Khaw K.T., Wareham N., Luben R., Bingham S., Oakes S., Welch A., Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001, 322:15-18.
37. McCarter R.J., Hempe J.M., Gomez R., Chalew S.A. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004, 27:1259-1264.
38. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
39. Jinnouchi Y., Sano H., Nagai R., Hakamata H., Kodama T., Suzuki H., Yoshida M., Ueda S., Horiuchi S. Glycolaldehyde-modified low density lipoprotein leads macrophages to foam cells via the macrophage scavenger receptor. J. Biochem. 1998, 123:1208-1217.
40. Bulteau A.L., Szweda L.I., Friguet B. Age-dependent declines in proteasome activity in the heart. Arch. Biochem. Biophys. 2002, 397:298-304.
41. Stolzing A., Widmer R., Jung T., Voss P., Grune T. Degradation of glycated bovine serum albumin in microglial cells. Free Radic. Biol. Med. 2006, 40:1017-1027.
42. Portero-Otin M., Pamplona R., Ruiz M.C., Cabiscol E., Prat J., Bellmunt M.J. Diabetes induces an impairment in the proteolytic activity against oxidized proteins and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat liver and kidney. Diabetes 1999, 48:2215-2220.
43. Miyata S., Liu B.F., Shoda H., Ohara T., Yamada H., Suzuki K., Kasuga M. Accumulation of pyrraline-modified albumin in phagocytes due to reduced degradation by lysosomal enzymes. J. Biol. Chem. 1997, 272:4037-4042.
44. Kanter J.E., Johansson F., LeBoeuf R.C., Bornfeldt K.E. Do glucose and lipids exert independent effects on atherosclerotic lesion initiation or progression to advanced plaques?. Circ. Res. 2007, 100:760-781.
45. Cervantes-Laurean D., Roberts M.J., Jacobson E.L., Jacobson M.K. Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment. Free Radic. Biol. Med. 2005, 38:786-795.
46. Mason G.G., Hendil K.B., Rivett A.J. Phosphorylation of proteasomes in mammalian cells. Identification of two phosphorylated subunits and the effect of phosphorylation on activity. Eur. J. Biochem. 1996, 238:453-462.
47. Arendt C.S., Hochstrasser M. Eukaryotic 20S proteasome catalytic subunit propeptides prevent active site inactivation by N-terminal acetylation and promote particle assembly. EMBO J. 1999, 18:3575-3585.
48. Gonzalez-Dosal R., Sorensen M.D., Clark B.F., Rattan S.I., Kristensen P. Phage-displayed antibodies for the detection of glycated proteasome in aging cells. Ann. N. Y. Acad. Sci. 2006, 1067:474-478.
49. Reinheckel T., Sitte N., Ullrich O., Kuckelkorn U., Davies K.J., Grune T. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem. J. 1998, 335:637-642.
50. Ishii T., Sakurai T., Usami H., Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry 2005, 44:13893-13901.
51. Strack P.R., Waxman L., Fagan J.M. Activation of the multicatalytic endopeptidase by oxidants. Effects on enzyme structure. Biochemistry 1996, 35:7142-7149.
52. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
53. Marfella R., D'Amico M., Esposito K., Baldi A., Di Filippo C., Siniscalchi M., Sasso F.C., Portoghese M., Cirillo F., Cacciapuoti F., Carbonara O., Crescenzi B., Baldi F., Ceriello A., Nicoletti G.F., D'Andrea F., Verza M., Coppola L., Rossi F., Giugliano D. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 2006, 55:622-632.
54. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
55. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 1999, 344:109-116.
56. Lapolla A., Flamini R., Dalla Vedova A., Senesi A., Reitano R., Fedele D., Basso E., Seraglia R., Traldi P. Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin. Chem. Lab. Med. 2003, 41:1166-1173.
57. Odani H., Shinzato T., Matsumoto Y., Usami J., Maeda K. Increase in three alpha, beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem. Biophys. Res. Commun. 1999, 256:89-93.
58. McLellan A.C., Phillips S.A., Thornalley P.J. The assay of methylglyoxal in biological systems by derivatization with 1, 2-diamino-4, 5-dimethoxybenzene. Anal. Biochem. 1992, 206:17-23.
59. Zheng L., Nukuna B., Brennan M.L., Sun M., Goormastic M., Settle M., Schmitt D., Fu X., Thomson L., Fox P.L., Ischiropoulos H., Smith J.D., Kinter M., Hazen S.L. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 2004, 114:529-541.
60. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., Singh P., Anantharamaiah G.M., Chait A., Brunzell J., Geary R.L., Oram J.F., Heinecke J.W. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl Acad. Sci. USA 2004, 101:13032-13037.
61. Suarna C., Dean R.T., May J., Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1616-1624.
62. Sebekova K., Schinzel R., Ling H., Simm A., Xiang G., Gekle M., Munch G., Vamvakas S., Heidland A. Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1. Cell. Mol. Biol. (Noisy-le-grand) 1998, 44:1051-1060.
63. Glomb M.A., Monnier V.M. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J. Biol. Chem. 1995, 270:10017-10026.
64. Mendez D.L., Jensen R.A., McElroy L.A., Pena J.M., Esquerra R.M. The effect of non-enzymatic glycation on the unfolding of human serum albumin. Arch. Biochem. Biophys. 2005, 444:92-99.
65. Voges D., Zwickl P., Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 1999, 68:1015-1068.
66. Groll M., Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim. Biophys. Acta 2004, 1695:33-44.